A conjugate comprising: a) a ligand for a glutathione transporter; wherein the ligand is selected from the group consisting of: glutathione, S-(p-bromobenzyl)glutathione, gamma-(L-gamma-azaglutamyl)-S-(p-bromobenzyl)-L-cysteinylglycin, S-butylglutathione, S-decylglutathione, glutathione reduced ethyl ester, glutathionesulfonic acid, S-hexylglutathione, S-lactoylglutathione, S-methylglutathione, S-(4-nitrobenzyl)glutathione, S-octylglutathione, S-propylglutathione, n-butanoyl gamma-glutamylcysteinylglycine, ethanoyl gamma-glutamylcysteinylglycine, hexanoyl gamma-glutamylcysteinylglycine, octanoyl gamma-glutamylcysteinylglycine, dodecanoyl gamma-glutamylcysteinylglycine, GSH monoisopropyl ester (N-(N-L-glutamyl-L-cysteinyl)glycine 1-isopropyl ester sulfate monohydrate) and glutathione derivatives of the formula I: wherein Z=CH 2 and Y=CH 2, or Z=O and Y = C=O; R 1 and R 2 are independently selected from the group consisting of H, linear or branched alkyl, aralkyl, cycloalkyl, heterocycles, ethers or polyethers, and where R 1 -R 2 together have 2-20C atoms and form a macrocycle with the remainder of formula I; R 3 is selected from the group consisting of H and CH 3; R4 is selected form the group consisting of 6-8C alkyl, benzyl, naphthyl and a therapeutically active compound; and, R5 is selected from the group consisting of H, phenyl, CH 3 - and CH 2 -phenyl; or, a pharmaceutically acceptable salt thereof, and, b) a liposome comprising an anthracycline, wherein the ligand in a) is conjugated to the liposome in b). a) a ligand for a glutathione transporter; wherein the ligand is selected from the group consisting of: glutathione, S-(p-bromobenzyl)glutathione, gamma-(L-gamma-azaglutamyl)-S-(p-bromobenzyl)-L-cysteinylglycin, S-butylglutathione, S-decylglutathione, glutathione reduced ethyl ester, glutathionesulfonic acid, S-hexylglutathione, S-lactoylglutathione, S-methylglutathione, S-(4-nitrobenzyl)glutathione, S-octylglutathione, S-propylglutathione, n-butanoyl gamma-glutamylcysteinylglycine, ethanoyl gamma-glutamylcysteinylglycine, hexanoyl gamma-glutamylcysteinylglycine, octanoyl gamma-glutamylcysteinylglycine, dodecanoyl gamma-glutamylcysteinylglycine, GSH monoisopropyl ester (N-(N-L-glutamyl-L-cysteinyl)glycine 1-isopropyl ester sulfate monohydrate) and glutathione derivatives of the formula I: wherein Z=CH 2 and Y=CH 2, or Z=O and Y = C=O; R 1 and R 2 are independently selected from the group consisting of H, linear or branched alkyl, aralkyl, cycloalkyl, heterocycles, ethers or polyethers, and where R 1 -R 2 together have 2-20C atoms and form a macrocycle with the remainder of formula I; R 3 is selected from the group consisting of H and CH 3; R4 is selected form the group consisting of 6-8C alkyl, benzyl, naphthyl and a therapeutically active compound; and, R5 is selected from the group consisting of H, phenyl, CH 3 - and CH 2 -phenyl; or, a pharmaceutically acceptable salt thereof, and, wherein Z=CH 2 and Y=CH 2, or Z=O and Y = C=O; R 1 and R 2 are independently selected from the group consisting of H, linear or branched alkyl, aralkyl, cycloalkyl, heterocycles, ethers or polyethers, and where R 1 -R 2 together have 2-20C atoms and form a macrocycle with the remainder of formula I; R 3 is selected from the group consisting of H and CH 3; R4 is selected form the group consisting of 6-8C alkyl, benzyl, naphthyl and a therapeutically active compound; and, R5 is selected from the group consisting of H, phenyl, CH 3 - and CH 2 -phenyl; or, a pharmaceutically acceptable salt thereof, and, b) a liposome comprising an anthracycline, wherein the ligand in a) is conjugated to the liposome in b).